SUBSCRIBE
SUBSCRIBE

Boehringer Ingelheim Pharmaceuticals, Inc.

NEWS
Drug Development
Inflammatory Bowel Disease Insight Report: Current Therapies, Drug Pipeline and Outlook
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
November 18, 2019
 · 
33 min read
 · 
Tracy Lawton
Business
Boehringer CFO Quits After 16 Months on the Job Over Differences in Strategy
Boehringer’s global head of information technology, Michael Schmelmer, will replace Menne on Jan. 1, 2018.
December 15, 2017
 · 
2 min read
 · 
Mark Terry
Business
Boehringer Focuses on RNA
Boehringer has made a big push into RNA this month.
November 27, 2017
 · 
1 min read
 · 
Karl Thiel
Business
Boehringer, MiNA Therapeutics Forge EUR 307M R&D NASH Tie-Up
Fresh off the heels of a $201M liver disease R&D deal with Dicerna, Boehringer Ingelheim has struck another deal targeting liver disease with MiNA Therapeutics.
November 8, 2017
 · 
2 min read
 · 
Alex Keown
AIDS Drugs Cocktail Better Than Single Nevirapine Dose In Newborns
October 19, 2005
 · 
1 min read
Policy
Pain Drug Mobic Shows Increased Risk - FDA Scientist
October 19, 2005
 · 
1 min read
Policy
US Warns Of Safety Risks Of Boehringer AIDS Drug
October 19, 2005
 · 
1 min read
New Help For Urinary Dysfunction
October 19, 2005
 · 
1 min read
Load More
JOBS
IN THE PRESS
FDA
Boehringer Ingelheim Pharmaceuticals, Inc. Release: FDA Approves Pradaxa® (Dabigatran Etexilate Mesylate) For Treatment And Reduction In The Risk Of Recurrence Of Deep Venous Thrombosis And Pulmonary Embolism
April 7, 2014
 · 
15 min read
Pharm Country
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Pradaxa® (dabigatran etexilate mesylate) Data To Be Presented At American College of Cardiology Scientific Session (ACC.14)
March 25, 2014
 · 
8 min read
Policy
Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company Diabetes Drug Empagliflozin Wins EU Panel’s Backing
March 21, 2014
 · 
5 min read
Drug Development
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Phase III Study Of Dabigatran Etexilate Mesylate Met Primary Endpoint For Six-Month Treatment Of Deep Vein Thrombosis (DVT) And/Or Pulmonary Embolism (PE)
December 17, 2013
 · 
13 min read
Pharm Country
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Long-Term Data Presented At American Heart Association Scientific Sessions Reinforce Safety Profile Of Pradaxa® (dabigatran etexilate mesylate)
November 18, 2013
 · 
12 min read
Business
Boehringer Ingelheim Pharmaceuticals, Inc.'s Jeff Huth Elected as National Pharmaceutical Council’s Chairman of the Board
November 8, 2013
 · 
2 min read
Drug Development
Boehringer Ingelheim Pharmaceuticals, Inc.'s Interferon-Free Hepatitis C Treatment Portfolio Strengthened by Promising Interim Phase 2a Data
November 4, 2013
 · 
9 min read
Pharm Country
Boehringer Ingelheim Pharmaceuticals, Inc. to Present Latest Data from Robust Respiratory Portfolio at American College of Chest Physicians (ACCP) Annual Meeting
October 25, 2013
 · 
10 min read
Drug Development
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Investigational Interferon-Free Regimen Demonstrates Undetectable Hepatitis C Virus in All Patients Reaching End of Treatment in Ongoing Phase 2 Trial
October 8, 2013
 · 
8 min read
Drug Development
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Investigational Interferon-Free Regimen Demonstrates Undetectable Hepatitis C Virus in All Patients Reaching End of Treatment in Ongoing Phase 2 Trial
October 8, 2013
 · 
8 min read
Load More